

Please replace the paragraph on page 24, lines 5-8 as follows:

A solution of ramoplanin at 10 mg/ml of activity was prepared in NaCl 0.9% (w/vol).

B12

The solution was sterilized by filtration with 0.22  $\mu$ m pore-size filters.

### IN THE CLAIMS

Please amend the claims as follows.

--7. (Twice Amended) A formulation according to claim 1 wherein the fat emulsion product employed for the preparation of said formulation comprises a composition selected from those reported in the following tables:

	Fat emulsion product 1	Fat emulsion product 2	Fat emulsion product 3
Soybean oil (w/vol)	10%	20%	5%
Safflower oil (w/vol)	--	--	5%
Egg yolk phospholipids (w/vol)	1.2%	1.2%	1.2%
Glycerol (w/vol)	2.25%	2.25%	2.5%
Fatty acids composition of vegetable oils (w/vol)			
Linoleic acid	50%	50%	65.8%
Oleic acid	26%	26%	17.7%
Palmitic acid	10%	10%	8.8%
Linolenic acid	9%	9%	4.2%
Stearic acid	3.5%	3.5%	3.4%
Osmolarity (mOsm/L)	260	268	276
Approximate pH	8	8	8
Fat particle size ( $\mu$ m)	0.5	0.5	0.4
Caloric value (cal/ml)	1.1	2.0	1.1
Size (ml)	50, 100	50, 100	25, 50

B13  
conclude

	250 or	250 or	100, 200
	500	500	Or 500
	Fat emulsion product 4	Fat emulsion product 5	Fat emulsion product 6
Soybean oil (w/vol)	10%	10%	20%
Safflower oil (w/vol)	10%	--	--
Egg yolk phospholipids (w/vol)	1.2%	1.2%	1.2%
Glycerol (w/vol)	2.5%	2.5%	2.5%
Fatty acids composition of vegetable oil (w/vol)			
Linoleic acid	65.8%	54.5%	54.5%
Oleic acid	17.7%	22.4%	22.4%
Palmitic acid	8.8%	10.5%	10.5%
Linolenic acid	4.2%	8.3%	8.3%
Stearic acid	3.4%	4.2%	4.2%
Osmolarity (mOsm/L)	258	284	292
Approximate pH	8.3	8.3	8.3
Fat particle size ( $\mu\text{m}$ )	0.4	0.4	0.4
Caloric value (cal/ml)	2.0	1.1	2.0
Size (ml)	25, 50	100, 200	200 or
	200 or	Or 500	550
	500		

and water for injection is from quite small to 100%.

B14  
pass

14. (Twice Amended) A formulation according to claim 1 for treatment of infections caused by microorganisms whose proliferation is inhibited, reduced, alleviated, or arrested in the presence of ramoplanin or an antibiotic of the ramoplanin family.

*B11*  
*agrade*  
15. (Twice Amended) A method of treating Gram positive infections, comprising administering the formulation according to claim 1 to a patient in need thereof.--

Please add the following claims.

*B15*  
--36. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor  $A_2$ .

37. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor  $A_2'$ .

38. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor  $A_1$ .

39. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor  $A_1'$ .

40. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor  $A_3$ .

41. (New) The formulation according to Claim 1, wherein the member of the ramoplanin family of formula I is factor  $A_3'$ .

*qds*  
42. (New) The method according to Claim 15, wherein the Gram positive infection is at least one member selected from the group consisting of bacteremia, endocarditis, and pneumonia.--